Brooks Laboratories Ltd
NSE:BROOKS

Watchlist Manager
Brooks Laboratories Ltd Logo
Brooks Laboratories Ltd
NSE:BROOKS
Watchlist
Price: 159.99 INR 2% Market Closed
Market Cap: 4.2B INR
Have any thoughts about
Brooks Laboratories Ltd?
Write Note

Brooks Laboratories Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Brooks Laboratories Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Brooks Laboratories Ltd
NSE:BROOKS
Operating Income
â‚ą17.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-12%
Divi's Laboratories Ltd
NSE:DIVISLAB
Operating Income
â‚ą19.4B
CAGR 3-Years
-11%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Suven Life Sciences Ltd
NSE:SUVEN
Operating Income
-â‚ą1.7B
CAGR 3-Years
-10%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Operating Income
-â‚ą83.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Syngene International Ltd
NSE:SYNGENE
Operating Income
â‚ą5.5B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
N/A
I
Innova Captab Ltd
NSE:INNOVACAP
Operating Income
â‚ą1.3B
CAGR 3-Years
39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Brooks Laboratories Ltd
Glance View

Market Cap
4.2B INR
Industry
Life Sciences Tools & Services

Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. The firm has two manufacturing plants, which are located at Baddi in Himachal Pradesh and Vadodara in Gujarat. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.

BROOKS Intrinsic Value
45.18 INR
Overvaluation 72%
Intrinsic Value
Price

See Also

What is Brooks Laboratories Ltd's Operating Income?
Operating Income
17.4m INR

Based on the financial report for Jun 30, 2024, Brooks Laboratories Ltd's Operating Income amounts to 17.4m INR.

What is Brooks Laboratories Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-12%

Back to Top